therefore must operate efficiently to respond promptly to the ever-changing energy needs as required by the rest of the body's function. Mitochondrial abnormalities and reduced capacity to generate ATP can have a profound impact in heart failure (HF). Abnormal mitochondria are also linked to myocyte injury because they are a major source of reactive oxygen species production that can induce cellular damage. Abnormal mitochondria also promote programmed cell death through the release of cytochrome c into the cytosolic compartment and activation of caspases (3) .
Progression to HF is associated with a decline in energy reserve capacity that ultimately reaches a threshold after which compensatory mechanisms can no longer support the decreasing energy supply.
Moreover, skeletal muscles also show mitochondrial dysfunction in HF, thus contributing to exercise intolerance (4). Mitochondrial dysfunction is also seen in patients with renal insufficiency (5) and in insulin resistance (6) . Because patients with HF often have both renal insufficiency and insulin resistance, treating mitochondrial dysfunction in HF hold promise to help through cardiac and extracardiac mechanisms.
In this issue of JACC: Basic to Translational Science, Previous studies with elamipretide showed that the drug directly improved energetics in various animal models (8, 9) . The study by Chatfield et al. (7) Science author instructions page.
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The study by Chatfield et al. (7) 
